logo-loader
viewNemaura Medical Inc

Nemaura CEO to tout flagship SugarBEAT glucose monitors at major diabetes conference

The symposia will focus on the development of Nemaura’s SugarBEAT continuous glucose monitors, the product’s application to diabetes management, clinical data and recent user experiences

Nemaura Medical Inc - Nemaura Medical Inc CEO Dr Faz Chowdhury will present at major diabetes conference in Barcelona, Spain later this month to tout flagship SugarBEAT continuous glucose monitors
The company's SugarBEAT system works for patients with diabetes or prediabetes by testing their blood glucose levels using a sensor on the skin, rather than using a needle

Nemaura Medical Inc (NASDAQ:NMRD) said Thursday that CEO Dr Faz Chowdhury will present at a major diabetes conference in Barcelona, Spain later this month to tout the company's flagship SugarBEAT glucose monitors.

In addition to CEO Chowdhury, Dr Fred Schaebsdau, the company’s vice president of strategic alliances, and Dr Iain Cranson, a diabetes specialist based in the UK, will also join in the presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 19.

The evening symposia will focus on the historic development of Nemaura’s SugarBEAT continuous glucose monitors, the product’s application to all categories of diabetics and diabetes management, clinical data and recent user experiences, the company said in a statement.

READ: Nemaura receives $8 million credit facility from major shareholders

The presentation is titled: “SugarBEAT® Non-Invasive CGM User Study Results: Diagnostic and Monitoring Applications Across Different Patient Types and Clinical Settings.”

"We are very pleased to be holding this symposia at this premier industry conference,” Chowdhury said. “We will be reporting study results from our first users, as well as sharing prior clinical data and user experiences. We also plan to discuss our commercial launch plans, including product availability in different territories.”

He added: “We look forward to highlighting how SugarBEAT differs from current invasive CGM technologies and the potential to expand the addressable market to include Type 2 diabetics and pre-diabetics.”

The EASD Annual Meeting is Europe’s largest and most prominent meeting on diabetes. The scientific program offers researchers and healthcare professionals the opportunity to share ideas and learn about cutting-edge research and technology, ground-breaking studies and the significant advances in diabetes research, treatment and care.

The Loughborough, England-based company's SugarBEAT system works for patients with diabetes or prediabetes by testing their blood glucose levels using a sensor on the skin, rather than using a needle.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Nemaura Medical Inc

Price: 5.01 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $104.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read